tiprankstipranks
Trending News
More News >

Destiny Pharma’s XF-73 Gel Reduces Antibiotic Need

Destiny Pharma’s XF-73 Gel Reduces Antibiotic Need

Destiny Pharma plc (GB:DEST) has released an update.

Confident Investing Starts Here:

Destiny Pharma plc’s Phase 2b clinical trial results revealed that patients treated with XF-73 Nasal gel required significantly fewer post-surgical antibiotics compared to the placebo group. These findings underscore the potential of XF-73 in enhancing antimicrobial stewardship and patient safety by reducing infection risk and maintaining antibiotic efficacy. The company plans to present further data at the ID Week conference and is preparing for Phase 3 studies to seek regulatory approval.

For further insights into GB:DEST stock, check out TipRanks’ Stock Analysis page.

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.

Report an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App